Skip to main content
. 2021 Feb 4;14(2):e238851. doi: 10.1136/bcr-2020-238851

Figure 1.

Figure 1

Clinical course and remission before and after treatment with tofacitinib. Images of joint inflammation with bilateral metacarpophalangeal joint synovitis (arrows) before and after treatment with tofacitinib (A). Reduction in TJC, SJC, DAS28-CRP and CRP scores from commencement of tofacitinib treatment at time 0 and remission at week 31 (B). Dashed red line (DAS28-CRP) indicates clinical remission (>2.6) at week 20. CRP, C-reactive protein; SJC, swollen joint count; TJC, tender joint count.